CAMP4 Therapeutics Corporation Statistics
Share Statistics
CAMP4 Therapeutics Corporation has 19.51M shares outstanding. The number of shares has increased by -95.65% in one year.
| Shares Outstanding | 19.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.79M |
| Failed to Deliver (FTD) Shares | 2.86K |
| FTD / Avg. Volume | 2.59% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -2.94 and the forward PE ratio is null.
| PE Ratio | -2.94 |
| Forward PE | null |
| PS Ratio | 1.47 |
| Forward PS | 0.6 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | n/a |
Enterprise Valuation
CAMP4 Therapeutics Corporation has an Enterprise Value (EV) of 274.34M.
| EV / Earnings | -2.94 |
| EV / Sales | 1.47 |
| EV / EBITDA | -31.46 |
| EV / EBIT | -31.46 |
| EV / FCF | -8.06 |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is -3.4%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -3.4% |
| Revenue Per Employee | 3.21M |
| Profits Per Employee | -1.61M |
| Employee Count | 58 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -525.00K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 19.19% in the last 52 weeks. The beta is 1.76, so CAMP4 Therapeutics Corporation's price volatility has been higher than the market average.
| Beta | 1.76 |
| 52-Week Price Change | 19.19% |
| 50-Day Moving Average | 7.93 |
| 200-Day Moving Average | 4.73 |
| Relative Strength Index (RSI) | 50.73 |
| Average Volume (20 Days) | 110.58K |
Income Statement
In the last 12 months, CAMP4 Therapeutics Corporation had revenue of $186.23M and earned -$93.26M in profits. Earnings per share was $-2.52.
| Revenue | 186.23M |
| Gross Profit | 66.98M |
| Operating Income | -8.72M |
| Net Income | -93.26M |
| EBITDA | -8.72M |
| EBIT | -8.72M |
| Earnings Per Share (EPS) | -2.52 |
Balance Sheet
The company has $41.93M in cash and $240.44M in debt, giving a net cash position of -$198.51M.
| Cash & Cash Equivalents | 41.93M |
| Total Debt | 240.44M |
| Net Cash | -198.51M |
| Retained Earnings | -168.82M |
| Total Assets | 281.24M |
| Working Capital | 69.26M |
Cash Flow
In the last 12 months, operating cash flow was -$22.93M and capital expenditures -$11.10M, giving a free cash flow of -$34.03M.
| Operating Cash Flow | -22.93M |
| Capital Expenditures | -11.10M |
| Free Cash Flow | -34.03M |
| FCF Per Share | null |
Margins
Gross margin is 35.97%, with operating and profit margins of -4.68% and -50.08%.
| Gross Margin | 35.97% |
| Operating Margin | -4.68% |
| Pretax Margin | -49.8% |
| Profit Margin | -50.08% |
| EBITDA Margin | -4.68% |
| EBIT Margin | -4.68% |
| FCF Margin | -18.27% |
Dividends & Yields
CAMP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -31.7% |
| FCF Yield | -21.95% |
Analyst Forecast
The average price target for CAMP is $18, which is 126.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 126.4% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Feb 2, 2024. It was a backward split with a ratio of 1:23.
| Last Split Date | Feb 2, 2024 |
| Split Type | backward |
| Split Ratio | 1:23 |
Scores
| Altman Z-Score | 0.07 |
| Piotroski F-Score | 5 |